All In Biotech

Drug Trial Radar · NCT02639520

Efficacy of CLR Compared to Fosfomycin Trometamol in Acute Lower uUTIs

A Double-blind, Controlled, Parallel-group, Randomized, Multicenter Clinical Trial to Assess the Efficacy and Safety of a Herbal Drug Containing Centaury, Lovage Root and Rosemary Leaf (CLR) in Comparison to Fosfomycin Trometamol for the Treatment of Acute Lower Uncomplicated Urinary Tract Infections (uUTIs) in Women

Last checked: Nov 20, 2026Latest source record: Jul 28, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 659 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

659

Actual

Start

Dec 2015

Primary completion

Jun 2017

Study completion Jun 29, 2017

Sponsor

Lead sponsor
Bionorica SEIndustry
Sponsor type
Industry
First posted
Dec 24, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
Female only, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To demonstrate non-inferiority of a non-antibiotic therapy with CLR versus an antibiotic treatment with fosfomycin trometamol in women suffering from acute lower uUTIs as measured by the proportion of patients who received an additional antibiotic treatment for acute lower uUTIs during the trial.

Conditions

  • Urinary Tract Infection

Interventions

  • Canephron® NDrug

    2 tablets 3 times a day for 7 days

  • Fosfomycin trometamolDrug

    1 sachet of 8 g of granules; one single dose on Day 1

  • Canephron® N-placeboDrug

    2 tablets 3 times a day for 7 days

  • Fosfomycin trometamol-placeboDrug

    1 sachet of 8 g of granules; one single dose on Day 1

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Intake of any additional antibiotic medication for acute lower uUTIs between Visit 1 and Visit 4Time frame: within 38 days after Visit 1 (=day 1)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Justus-Liebig-Universität

    Giessen, Hesse, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.